Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

Completed

Conditions studied: Hypertrophic Cardiomyopathy

In brief

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.

Key facts

Study ID

NCT02234336

Run by

Mayo Clinic

People needed

110

Starts

2014-10-01

Expected to finish

2017-07-25

Last updated by the study team

2019-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically and echocardiographically defined hypertrophic cardiomyopathy.
• Clinically indicated transthoracic echocardiography as part of the medical evaluation.
• No contradiction to administration of ultrasonic echocardiography contrast.
• Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
• No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
• Age 18 years and older

You may not qualify if…

• Insufficient image quality for determination of maximal wall thickness.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.